Day One Biopharmaceuticals, Inc. - DAWN

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
May 15, 2026 SCHEDULE 13G/A Vestal Point Capital, LP 0.0% 0 View
May 15, 2026 SCHEDULE 13G/A Ryan Wilder 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Fund XI, L.P. 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Associates XI, L.P. 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Associates XI, LLC 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Opportunity Fund I, L.P. 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Associates Opportunity I, L.P. 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Associates Opportunity I, LLC 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Opportunity Fund II, L.P. 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Associates Opportunity II, L.P. 0.0% 0 View
May 14, 2026 SCHEDULE 13G/A Atlas Venture Associates Opportunity II, LLC 0.0% 0 View
Apr 27, 2026 SCHEDULE 13D/A — — — View
Apr 13, 2026 SCHEDULE 13D/A — — — View
Apr 07, 2026 SCHEDULE 13G/A FMR LLC 0.0% 23,640 View
Apr 07, 2026 SCHEDULE 13G/A Abigail P. Johnson 0.0% 23,640 View
Mar 26, 2026 SCHEDULE 13G/A The Vanguard Group 0.0% 0 View
Mar 19, 2026 SCHEDULE 13G Glazer Capital, LLC 5.4% 5,615,390 View
Mar 19, 2026 SCHEDULE 13G Paul J. Glazer 5.4% 5,615,390 View
Feb 17, 2026 SCHEDULE 13G Vestal Point Capital, LP 5.1% 5,200,000 View
Feb 17, 2026 SCHEDULE 13G Ryan Wilder 5.1% 5,200,000 View
Feb 05, 2026 SCHEDULE 13G/A FMR LLC 5.6% 5,717,008 View
Feb 05, 2026 SCHEDULE 13G/A Abigail P. Johnson 5.6% 5,717,008 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.